Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.82 |
| ▸ | USP2 | O75604 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | INPP5D | Q92835 | 2/20 | 0.58 |
| ▸ | CDC25A | P30304 | 3/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | OSBP | P22059 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.47 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL29153013 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL15935528 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14490136 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL25277367 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14360501 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL23647982 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL18504407 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL3421500 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL21000300 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL17049790 | 0.90 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | NPC1L1 3549/4885USP2 2284/4885LMNA 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.